Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 20/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15933941 | 0.80 | GPBAR1 (0.59) | GPBAR1 | |
| SCHEMBL27988819 | 0.80 | GPBAR1 (0.54) | GPBAR1 | |
| Hydrochloric Acid SCHEMBL27988803 | 0.79 | GPBAR1 (0.53) | GPBAR1 | |
| SCHEMBL30910058 | 0.78 | SIGMAR1 (0.53) | GPBAR1 | |
| SCHEMBL26091834 | 0.78 | SIGMAR1 (0.53) | GPBAR1 | |
| SCHEMBL29220800 | 0.77 | BRD4 (0.43) | GPBAR1 | |
| SCHEMBL30910160 | 0.77 | BRD4 (0.43) | GPBAR1 | |
| SCHEMBL15060098 | 0.75 | GPBAR1 (0.51) | GPBAR1CHRM5SLC6A2TSPOGPR183 | |
| SCHEMBL30910095 | 0.75 | MEN1 (0.40) | — | |
| SCHEMBL30379039 | 0.75 | BRD4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | GLP1R, GPR119, TRHR | GPBAR1 46/4885CHRM5 86/4885SLC6A2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.